Abstract:

Objective To systematically assess the efficacy and safety of stem cell transplantation in the treatment of idiopathic dilated cardiomyopathy. Methods China Biomedical Literature Database on disc, CNKI, VIP, Wanfang Data, Cochrane Controlled Trails Register, OVID Medline and EMBASE were searched. Two researchers independently extracted information, which was then cross-checked by each other. The primary parameters of therapeutic effects were mortality and heart failure questionnaire, the secondary parameters of therapeutic effects were left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVED) and 6-minute walking distance, and the parameter of safety was prevalence of adverse events. Meta-analysis was performed with RevMan 5.0.2 software. Results Seven randomized clinical trials (RCT) were enrolled, and 263 patients were included. Meta-analysis revealed that there was no significant difference in 3-year mortality between stem cell transplantation combined with standard therapy and single standard drug therapy, stem cell transplantation combined with standard therapy did not performed better than single standard drug therapy in improving LVEF 3 months after operation, and there was no stem cell transplantation-related adverse events. Conclusion The therapeutic effect of stem cell transplantation combined with standard therapy is no better than single standard drug therapy. However, due to the small scale and low quality of included RCT, more studies in large scale and high quality are needed to verify the results.

Key words: stem cell transplantation, dilated cardiomyopathy, Meta-analysis